|Acolbifene||Selective estrogen receptor modulator|
|Trade names||Femivia (tentative)|
|Other names||Prasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene|
Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women. It is intended for use by mouth. As of December 2017, it is in phase III clinical trials for this indication.